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Abstract 
The increasingly lower discovery rates of novel drugs with a novel mechanism of action are 
alarming especially anti-infective agents where concurrent increase in resistance rates are 
reported. This advocates expanding the search for innovative anti-infectives over a wide 
chemical space range.  
Accordingly, two targets are addressed in the novel approach of developing pathoblockers 
instead of classical antibacterials by quorum sensing inhibition. In the first target (PqsR), the 
focus is synthesizing small organic molecules to shed more light on the structure-functionality 
relationship of the compounds. Inverse agonists were shown to be the only pharmacological 
class to significantly inhibit the virulence factor pyocyanin in addition to identifying distinct 
amino acids for each drug class interaction. As to the second focus (PqsD), the developed 
inhibitors suffered from the lack of activity on the cellular level. So, design and linking of small 
molecule inhibitor to cell penetrating peptides were executed. While one of the conjugates 
retained its in vitro activity, no activity was yet observed in vivo.  
Lastly, a validated antibacterial target (RNA polymerase) was revisited via a novel approach. 
Macrocyclic peptides with improved α-helical propensities were designed and synthesized in 
order to improve activity in vitro and potentially on the cellular level. Even though this 
enhancement was not allied with an increase in biological activity, novel SAR insights were 
disclosed.  
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Zusammenfassung  
Alarmierend ist die Tatsache, dass die Zahl neuer Arzneistoffe mit innovativem Mechanismus 
ständig abnimmt. Das fällt bei Anti-Infektiva besonders schwer ins Gewicht, da gleichzeitig die 
Resistenzraten gegenüber verfügbaren Antibiotika steigen. Dies macht die Suche nach 
neuartigen Anti-Infektiva unter Einbeziehung des gesamten chemischen Strukturraums nötig.  
Dementsprechend wurden hier zwei Targets in einem neuartigen Ansatz zur Hemmung der 
Quorum Sensing Kommunikation adressiert, die zur Entwicklung von Pathoblockern anstelle 
der klassischen Antibiotika führen sollen. Im Fall des ersten Targets (PqsR) liegt der Fokus auf 
der Synthese von kleinen organischen Molekülen um den Zusammenhang zwischen Struktur 
und Funktion der Moleküle besser zu verstehen. Gezeigt werden konnte, dass nur inverse 
Agonisten in der Lage waren, die Bildung des Virulenzfaktors Pyocyanin signifikant zu 
hemmen. Außerdem wurden die für die Interaktion jeder Klasse spezifischen Aminosäuren 
identifiziert. Was das zweite Target (PqsD) anbelangt, hatten die entwickelten Inhibitoren 
keine Zellaktivität gezeigt. Aus diesem Grunde wurden diese Verbindungen mit Zell-
penetrierenden Peptiden verknüpft. Die Konjugate erwiesen sich als in vitro aber nicht in vivo 
aktiv. 
Des Weiteren wurde auf das validierte antibakterielle Target RNA Polymerase in einem 
neuartigen Ansatz zurückgekommen. Makrozyklische Peptide mit verbesserten a-helikalen 
Eigenschaften wurden konzipiert und synthetisiert um die in vitro Aktivität und eventuell die 
Zellaktivität zu erhöhen. Auch wenn die biologische Aktivität nicht gesteigert werden konnte, 
wurden neue Struktur-Wirkungs-Beziehungen erhalten. 
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1. Introduction 
A major drive for mankind discoveries has always been curiosity; the urge to find what’s lying 
there in the unknown, crossing barriers and seeking novelty in uncharted regions. Likewise, 
medicinal and organic chemists have undertaken extensive efforts to explore the drug 
discovery chemical space and overcome barriers posed by cellular compartments in order to 
deliver potent, safe, and stable therapies of tomorrow to today’s patients.  
1.1. Analysis of drugs discovery in respect of molecular size  
Upon inspecting currently available drugs on the market according to their molecular sizes, 
the first evident observation is that all drugs can be categorized into two big classes namely 
small organic molecules (SOMs) and biologics. Most of the SOMs exist below the 500 Daltons 
(Da) mark while the molecular weight (Mwt) of biologics is usually a few thousands of Daltons. 
For example, aspirin has a Mwt of 180 Da in comparison to monoclonal antibodies (mAbs) 
which usually have a Mwt of ~150,000 Da (Fig. 1). Genentech parallels this to the difference 
between a bicycle and a business jet. Even though this quite staggering difference in size and 
complexity both classes effectively exert diverse biological effects on various drug targets [1].  
 
 
 
 
 
 
 
 
 
The second observation is the huge gap between the two classes (500-100,000s Da) with 
Insulin and growth hormones as the most prominent examples of treatments occupying that 
Figure 1. A depiction of aspirin in comparison to a monoclonal antibody [1] 
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space. Peptide-based therapeutics elegantly bridge this gap possessing an amino acid based 
core as in biologics while maintaining some of the size and cell-penetrability of SOMs [1,2].  
A drug doesn’t have to be solely composed of one of the aforementioned classes. For example, 
one can combine SOMs with a cell-penetrating peptide (CPP) or make antibody-drug 
conjugates (ADCs) [3,4]. The latter have been gaining huge interest as it provides combining 
the different advantages of both biologics (specificity and safety) with the potency of SOMs. 
Such techniques would allow the permeation and/or selective delivery of a compound in high 
concentrations to target cells or cell compartments not accessible by SOMs alone [1–3]. Table 
1 provides a comparison of the properties of SOMs, peptides, biologics and mixed conjugates. 
 SOMs Peptides Biologics Mixed-conjugates 
Composition 
Synthetic organic 
compound 
Amino acids Amino acids 
Amino acids/ 
synthetic organic 
compounds 
Mwt <700 Da ~ 500 - 2000 >10,000 1000-150,000 
Physicochemical 
properties 
Well defined 
Fairly defined to 
complex 
Complex 
Preparation 
Chemical 
synthesis  
Chemical synthesis 
/ Biotechnological 
production 
Biotechnological 
production 
Chemical synthesis 
/ Biotechnological 
production 
Dosing route Usually Oral Typically i.v., s.c., i.m. 
Dose interval Few hours to days Days to months 
Serum half-life Short Relatively long  
Potency and 
selectivity 
Generally less 
selective 
High selectivity (affinity and potency) 
Immunogenicity No Unlikely Yes Yes 
Distribution 
To any 
combination of 
organs/cells 
Possible to any 
combination of 
organs/cells 
Usually limited to plasma and 
extracellular fluids 
Metabolism 
Typically via 
CYP450s 
via CYP450s and 
Proteolytic 
degradation 
Proteolytic 
degradation  
via CYP450s and 
Proteolytic 
degradation 
Excretion Mainly biliary and renal  Mostly recycled by body 
Target location Intracellular and extracellular  
Mostly 
extracellular 
Intracellular and 
extracellular 
Off-target activities 
By drug or its 
metabolites  
Unlikely 
By drug or its 
metabolites 
Table 1. Comparison of properties of small organic molecules, peptides, biologics, and mixed-conjugates. 
Adopted from [1–4] 
Thirty years ago, the rise in biologics led some pharmaceutical companies to focus on 
developing biologics solely while others remaining with the classical SOMs. However, 
currently, all “big pharma” are developing both types of drugs. It’s not a matter of choosing 
between the different classes but rather using them alone or in combination in order to 
discover novel therapies. 
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1.2. Cellular location of targets and its influence on drug class choice 
One of the most important – preferably early – steps in drug discovery is target identification, 
druggability, and validation [5]. In order to achieve that the target has to be accessible to the 
molecule and once bound block the site or the production of ligands eliciting an undesirable 
biological response i.e. the medications have to reach their site of action and be potent 
enough [6]. Therefore, the target’s location and properties of the site of action influence the 
choice of drug class (size).  
Besides Ion channels and transporters, all protein drug targets can be classified into three 
categories:  
 Enzymes: They are proteins required for catalyzing different reactions in the human 
body. They can be located inside cells or on the surface or in blood. 
 Intracellular receptors: For drugs targeting such receptors crossing of the cell 
membrane is required. Therefore, such molecules must have certain properties. These 
receptors can be located in the cytoplasm or the nucleus of the cells. 
 Extracellular receptors: On the contrary to the previous type, the receptors lay on the 
cell surface and thus no crossing of cellular barriers are required. Once the drug binds, 
a signal is transduced to the inside of the cell affecting cellular pathways. 
Biologics have long been believed to be too big for cellular penetration. Thus, they were 
utilized exclusively for extracellular targets on cells surfaces rather than intracellular ones 
leaving a lot of untapped potential targets [7]. However, recently Ferrone et al. were able to 
show that antibodies can penetrate cell membrane targeting intracellular phosphatases of 
regenerating liver stopping metastases. Even though, the underlying exact molecular 
mechanism might still be elusive [8–10].  
The assumption (Biologics are too big for cellular penetration) led to bias for using SOMs for 
targeting intracellular targets [11]. However, targeting protein-protein interactions (PPIs) for 
example has shown to be impervious to SOMs due to having huge surface areas and small 
contact points [12]. Thus, even though SOMs are easier to get into cells they are not potent 
enough to result in a biological response. In contrast, peptides and biologics possess high 
interaction surface area enabling high affinity as well as specificity to their targets [12]. It is 
therefore important to consider larger molecules – beyond the 500 Da mark – towards 
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“challenging” intracellular targets and how to modulate them in order to overcome the hurdle 
of intracellular penetration [12,13].  
1.3. Approaches to overcome biological barriers for drugs 
addressing intracellular targets 
Typically, irrespective of the compound class and route of administration, compounds are 
challenged by physical barriers such as the gastrointestinal tract (GIT), surface epithelia, blood 
brain barrier (BBB), and interstitial tissue [14]. In the case of compounds addressing 
intracellular targets, one or more additional obstacles of human nature (cell membranes 
and/or mitochondrial membrane) or of other species colonizing the human body i.e. microbes 
must be overcome. 
Molecular weight and size influences cell permeability and the techniques employed to 
improve drug to target accessibility. Nevertheless, there are three approaches generally 
pursued:  
1. Formulation and drug delivery technologies  
2. Chemical derivatization according to semi-empirical rules 
3. Coupling of “cargo” to peptides/proteins capable of cell penetration.  
The latter two points are discussed more in details in the following subtitles. 
1.3.1 Chemical derivatization according to semi-empirical rules 
One of the very first attempts to develop empirical correlations for permeation was the 
seminal work of Lipinski et al.. Lipinski’s “Rule of 5” (Ro5) focused on correlating 
physicochemical properties (polarity and size) of SOMs only and its influence on oral 
absorption and passive permeation [15]. The rule states mainly four parameters that can 
decrease permeation and oral absorption: 
 >5 H-bond donors 
 >10 H-bond acceptors 
 Molecular weight >500 Da 
 Calculated Log P (cLogP) >5 
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Other hypotheses were proposed adopting alternative metrics such as polar surface area 
(PSA), the number of rotatable bonds, and conformational flexibility as better predictors 
[13,14,16–19]. However, not all permeable compounds conform to those rules and vice versa. 
Therefore, these physicochemical “rules” should be used more as guidelines rather than 
absolute criteria. Especially handling natural products and compounds beyond the 500 Da 
mark (600-1200 Da) where many compounds are characterized by having a ‘chameleonic’ 
ability [13,19]. A well-known example of this is “cyclosporine A” which in aqueous solution 
adopts a conformation where its polar groups are exposed to the outside (high PSA) however 
when crossing the lipid membranes it changes its conformation burying its polar groups (low 
PSA) [13,14,16].  
Drugs for certain indications e.g. anti-infectives display added nonconformity to these rules as 
they are required to cross dissimilar permeation barriers i.e. the microbe cell wall (bacteria 
and fungi). In the case of intracellular infections, these drugs need to possess physicochemical 
properties to cross both barriers [20]. Cell membrane/wall permeation properties might vary 
immensely from humans to one microorganism and from one microorganism to the other. 
Thus, several attempts were undertaken to derive semi-empirical guidelines that apply for 
either single microorganisms or multiple ones e.g. Gram-positive vs. Gram-negative [21–23]. 
Another example of compounds which need to cross a second additional barrier is drugs 
targeting the mitochondria. Mitochondria have a further distinct double membrane with a 
strong internal negative potential. This taken into consideration, the design of molecules 
possessing a net cationic charge might lead to accumulation inside the negatively charged 
mitochondrial matrix [24]. 
Besides passive diffusion, prokaryotic and eukaryotic cells possess a set of transporters that 
can transport important cell substrates into the cell either with (passive) or against (active) 
gradient concentration. It also possesses efflux pumps and carrier proteins which expel 
xenobiotics and/or cellular products to the outside of the cell [14]. In theory, permeation could 
come about or could improve by designing compounds that mimic the active 
transporters/protein carriers’ natural substrates structurally rather than using 
physicochemical properties based models. For instance, if a ligand-based approach is 
undertaken to concept novel antagonists for an intracellular receptor whose agonist is actively 
transported, it is possible that the antagonists will be transported via the same set of 
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transporters. However, up till now, it has proven quite difficult to conceive drugs that are 
transporter specific [14].  
A steep drop-off in cellular permeability is observed once the Mwt of molecules exceeds the 
1000 Da mark making it unlikely that peptides can passively diffuse through the cellular 
membrane [13,16–18]. Nevertheless, some peptides are able to translocate into the cells 
either via energy-independent direct penetration or endocytosis [14]. Several techniques have 
been devolved for converting non-permeable peptides to permeable ones. Those techniques 
are focused mainly on optimizing two physical parameters (restricting conformation flexibility 
and decreasing polarity [25]): 
A) Macrocyclization: 
Cyclization of peptides by insertion of a side-to-side chain “staple” has shown to improve 
cellular permeability. This is because the polar amide backbone by such modification is 
shielded from the surrounding milieu hence decreasing polarity. The nature of the covalent 
stabilization also plays a role. If hydrocarbon side-to-side bridge were to be used, an increase 
in hydrophobicity occurs enhancing permeability through the lipids membrane. Additionally, 
stapling might lead to an increase in α-helical content improving peptide-cell membrane 
interactions and subsequently internalization [25,26].  
B) N-Methylation:  
Backbone N-methylation of peptide’s amide -NH- has shown to rigidify peptides conformation 
by stabilizing hydrogen-bonded conformations and decreasing the peptide backbone 
flexibility. Thus, N-methylation may serve to increase membrane permeability by stabilizing 
intramolecular hydrogen bonding in the membrane-associated state [27,28].  
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C) Increase net cationic charge  
Empirical observations concluded that in order to achieve cell-penetration, a net positive 
charge is desired for peptides. The overall positive charge is believed to promote better 
association of the peptides to the negatively charged phospholipid bilayer of cell membranes. 
Several studies demonstrated that structure guided optimization of peptides and replacement 
of amino acids not involved in binding to the target with Lysine or Arginine residues induces 
significant cell permeability. It must be noted that an unmonitored increase in cationic charge 
might lead to toxic peptides with cell-lysing property [29–32].  
Hence, biologics has long been thought incapable of targeting intracellular targets except for 
a few cases (see subtitle 1.2). Therefore, not many efforts have been pursued into structural 
modification of biologics for enhancing cellular penetration. The main approach pursued to 
enhance intracellular delivery is by decreasing the size of biologics to the minimal active 
sequence (MAS) and coupling the “cargo” to peptides that can translocate across cell 
membranes. The latter will be further discussed in the next subtitle.  
1.3.2 Coupling of “cargo” to peptides/proteins capable of cell 
penetration 
Some molecules have the ability to cross the cell membrane/wall barrier with relative ease 
compared to others. These could be passively diffused or actively transported substrates, and 
CPPs [33]. In what’s known as the “Trojan horse” strategy, an impermeable molecule of 
interest (cargo) can be linked to one of the aforementioned carrier entities granting it cell 
access [34–36]. However, this is not always straight forward as multiple parameters have to 
be thoroughly investigated such as the carrier of choice, linker stability (cleavable or not), site 
of drug conjugation and drug to carrier ratio [37].  
A classical application of this approach is design/synthesis of prodrugs by coupling an in vitro 
active drug to a natural transporter substrate such as sugars, amino acids, and bile acids [33]. 
An example of such “prodrug” approach is Valganciclovir the valyl ester prodrug of Ganciclovir 
(attached to the amino acid L-valine) that was demonstrated to be better internalized by 
means of peptide transporters PEPT1 and PEPT2 [38].  
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Longer amino acid chains namely peptide-based carriers have been shown to be a promising 
tool for improving intracellular drug delivery e.g. CPPs. These peptides are also known as 
protein transduction domains and are divided into 3 main classes: 1) Cationic peptides. 2) 
Hydrophobic peptides derived from secreted growth factors and cytokines. 3) Cell-type 
specific peptides [31,33,35,36].  
Even though the exact mechanistic of how these peptides manage cell membrane penetration 
is not fully elucidated, the general mechanism has been shown to be receptor-independent 
pinocytosis [31]. CPPs are very versatile tools in terms of their ability to translocate diverse set 
of molecules i.e. SOMs, other peptides, plasmids, antigens, enzymes, DNA, RNA, and biologics 
[36,39]. 
One of the early attempts for intracellular delivery of CPP-drug conjugates linked 
methotrexate (MTX) to a poly (L-Lysine) peptide [40]. The conjugate cellular uptake exceeded 
that of the free drug. Intracellularly, it was found that the carrier peptide is degraded by means 
of lysosomal enzymes releasing the free drug inside the cells leading to in vitro tumor growth 
inhibition. Another study, coupled Doxorubicin to D-penetratin and SynB1, the vectorized 
Doxorubicin displayed a 20-fold lower IC50 in Doxorubicin resistant cells due to enhanced 
uptake [41]. This effect was validated in an in vivo mouse model displaying rapid accumulation 
of the vectorized drug in Doxorubicin-resistant cells, thereby resulting in potent tumor 
cytotoxicity. 
Likewise, the coupling of CPPs to other peptides has been pursued creating a larger sequence 
capable of both cell penetration and displaying a biological effect. In one study, two peptides 
were isolated that interfere with the function of the transcription factor E2F (a key factor in 
the regulation of cell proliferation) displaying an antiproliferative effect in tumor cells [42]. 
The peptides were fused to a HTV-Tat derived CPP. The Tat containing peptides decreased the 
level of expression of targeted regulated genes in vivo resulting in inhibition of cell 
proliferation and induction of cell apoptosis. 
Although most CPPs have been shown to translocate in a receptor-independent manner and 
as such lack cell type specificity, some developed vectors have been shown to be receptor 
mediated. An example of that is substance P (SP) [43]. SP is an eleven-amino acids long peptide 
that is internalized by means of its natural GPCR cognate (NK1R, neurokinin-1 receptor). NK1R 
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is known to be over-expressed in glioblastoma. Rizk et al. took advantage of this information 
and covalently associated SP to intracellularly deliver proteins such as GFP, DNA fragments, 
and polystyrene beads up to 1 µm in diameter in a selective manner to cancerous cells.  
Whereas GFP was treated as a cargo in the previous example, a “supercharged” variant of GFP 
capable of cell membrane penetration has been devised with a net charge of +36 [44]. In a 
following study, the same lab used the +36 GFP as a transferor for the delivery of functional 
Cre recombinase enzyme – in vitro and in vivo – into mammalian cells [45]. 
In summary, it has been shown that engineered or naturally occurring transporters are 
capable of internalizing various molecules with a broad span of size and weight. Moreover, 
the relative size of the drug/cargo (SOM, peptide or protein) compared to its carrier (a single 
amino acid, peptides or proteins) might not be of utmost importance in determining 
permeability but rather the common substructures. 
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2. Aim of thesis  
By 2050, deaths attributable to antimicrobial resistance every year are estimated to be around 
10 million [46]. That is one fatality every three seconds. Such mortality rates are accelerating 
due to the concurrent increase in resistance to clinically used antibiotics (Abs) and the lack of 
innovation in the discovery of novel ones. One of the main microbial threats which this work 
helps to tackle are Gram negative bacteria namely Pseudomonas aeruginosa (PA) and 
Escherichia coli. The strategy adopted for this work aims to help in deaccelerating the 
aforesaid crisis by targeting:  
a) Novel targets that should not infer resistance but only block the bacterium’ 
pathogenicity [47] (Pseudomonas Quinolone signaling quorum sensing system, PQS-
QS) and 
b) A previously validated target (E. coli RNA polymerase) via a novel mode of action.  
A) PQS-QS system in Pseudomonas aeruginosa 
This work intends to tackle two targets in the PQS-QS system namely, PqsD and PqsR (also 
known as MvfR). In a previous work from our lab, PqsR inhibitors were derived from ligand-
based drug design where the natural agonist – a SOM – quinolone scaffold was interconverted 
into an inhibitor [48–50]. It was observed that the C-3 position might be of great influence on 
the compound’s pharmacology. In order to enable rational hit-to-lead optimization, a 
synthetic campaign focusing mainly on modifications at position 3 of different biophysical 
attributes is to be embarked on. The yielded compounds would be subjected to a series of 
heterologous assays with the aim to elucidate the link between structural variations and 
compound pharmacological class. Moreover, in silico studies are to be devised to gain more 
insights into protein-ligand interactions on the molecular level. Finally, the effect of the 
pharmacological profile on the inhibition of virulence factor pyocyanin is to be investigated.  
The first discovered hits addressing PqsD suffered from low to no activities in cell-based assays 
that do not correlate with the high potency in vitro [51]. In this work, we plan to link one of 
the top inhibitors by a covalent bond to previously reported PA CPPs to improve cellular 
permeability. Next, the synthesized SOM-peptide conjugate would be tested in vitro on PqsD 
and if the activity is maintained subsequently in a cell-based assay. 
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B) E. coli RNA polymerase 
In order to initiate transcription, the core RNAP enzyme needs to bind to protein factors 
forming the holoenzyme complex. Thus, the protein-protein interaction (PPI) surface between 
both proteins represents an attractive new mode/site of action. A previously identified 
peptide (P07) has been shown to be a micromolar inhibitor of RNAP and sigma factor 70 PPI 
in vitro only [52]. However, for a possible pharmaceutical application, improved activities on 
the cellular level, oral bioavailability, and resistance to proteolytic degradation are desired. 
Thus in the frame of this work, peptide sequence and structural modifications by the means 
of Alanine-scan, truncation, sidechain-to-sidechain macrocyclization are attempted. These 
modifications aim to first identify the residues suitable for exchange with azide and alkyne 
bearing un-natural amino acids without compromising activity. These groups will be used as 
templates for Copper (I)-catalyzed alkyne−azide cycloaddition (CuAAC) forming a triazolyl 
moiety in order to constrain the peptide in the α-helical form which is assumed to be the 
bioactive conformation. Thus, leading to a decrease in entropic penalty required to assume 
the α-helical form required for binding. Moreover, by increasing the α-helical content and 
decreasing anionic charges might lead to better permeation through E. coli cell wall. 
 
In conclusion, these studies aim to conceive and rationally optimise novel anti-infective 
molecules of different complexity and sizes (SOMs, peptides, SOM-peptide conjugates) 
addressing various challenges due to target location and nature as well as cell-permeability 
impediments. 
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3. Results  
 
3.1  Chapter A: Structure–functionality relationship and 
pharmacological profiles of Pseudomonas aeruginosa 
alkylquinolone quorum sensing modulators 
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3.2  Chapter B: Exploring the chemical space of ureidothiophene-2-
carboxylic acids as inhibitors of the quorum sensing enzyme PqsD 
from Pseudomonas aeruginosa 
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3.3  Chapter C: Hit optimization of an α-helical peptide: Ala-scan, 
truncation, and sidechain-to-sidechain macrocyclization of an RNA 
polymerase inhibitor 
 
This person contributed to this chapter: 
Monica Habib: Synthesis and purification of peptides 27, 28, 31, and 32. 
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4. Conclusion and Outlook 
The general objective of this thesis is to exploit the rational synthesis and design of novel anti-
infectives stemming from diverse starting points and of broad molecular weight range, 
favorably with a low chance of resistance development. Each drug class was optimized to 
overcome one or more hurdles interconnected with cellular penetration into bacteria, target 
topology, and pharmacology.  
Compounds discussed in this chapter will be designated by a letter indicating the 
corresponding manuscript and the Arabic number used in its respective chapter i.e. A1 
indicates compound 1 from publication A. 
4.1 Small organic molecule (PqsR) 
In subchapter 3.1, the main was to investigate structural requirements for functional 
interconversion and how this translates into pyocyanin inhibition. The testing of the 
synthesized compounds series in heterologous E. coli assay revealed four pharmacological 
profiles namely, agonist, inverse agonist, antagonist and biphasic modulators. The different 
pharmacological profiles were found to be controlled by subtle modifications at C-3 of the 
quinolone scaffold. A structure-functionality relationship was deduced where the presence of 
hydrogen bond donors, hydrogen bond acceptors, and hydrophobic substituents would yield 
an inverse agonist, an agonist, and an antagonist, respectively.  
E. coli was used as an initial screening step to allow investigation of agonistic and antagonistic 
activities independent of the pqs system in PA. In addition, due to the higher rates of efflux 
and metabolism as well as lower membrane permeability that would impede deriving a clear 
analysis of structure-functionality relationship for the compounds. Thus, these results needed 
to be validated in PA as well. The top compounds from each class were tested in PA and yielded 
the same profiles even for the peculiar biphasic compound excluding it as an assay artifact and 
acting as a validation of our E. coli assay. The hypothesis for such behavior has been laid 
however, an experimental investigation is still missing.  
Next, the top compounds were subjected to molecular modeling and docking. The observed 
computational model corroborated our biological results while identifying key amino acids for 
interaction with substituent at position 3 for each class of PqsR modulators class. The model 
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was also able to explain the importance of the 6-NO2 group for the interaction of the 
compounds. Yet, it appears that position 3 plays a bigger role in deciding drug modality. 
Top compounds from each class were tested for pyocyanin inhibition where it was found that 
only inverse agonists were able to significantly reduce virulence factor pyocyanin. This was 
explained by the prescience of constitutive basal activity in PqsR in a similar fashion to some 
GPCRs. Thus, it is not sufficient to only block the effect of the agonist to the receptor to the 
un-liganded level but the reduction of the receptor activity below basal as well. 
Altogether, we are confident this study displayed the utility of ligand-based originating 
compounds in studying receptors’ functional behavior. As well as, it provided novel insights 
that should be taken into consideration in the future rational design of PqsR inverse agonists. 
From a drug discovery perspective, this study revealed that pharmacological profile might be 
of more importance than the absolute IC50 values. Additionally, compound A27 displayed 
improved physicochemical attributes, metabolic stability, and toxicity profile (unpublished 
data), thus, rendering it a possible candidate for future in vivo studies.  
4.2 Peptide-Small organic molecule conjugates (PqsD) 
This study (subchapter 3.2) intended to improve intracellular penetration of in vitro active 
PqsD inhibitor. For achieving that two recently published CPP sequences were linked 
covalently to a PqsD inhibitor via a 3,6-dioxaoctanoic acid linker. Out of the two peptides, 
conjugate B25 retained some of the activity on PqsD in vitro. However, no activity was 
observed upon testing in the cell-based setting. From the in vitro activity, it can be deduced 
that the linker and linkage point has been properly chosen.  
Regarding the lack of cellular activity further experimentation is required as it could be due to 
any of the following reasons:  
1. The drug is internalized but is rapidly metabolized in the cell. This could be assessed by 
monitoring metabolic stability in the cell lysate. 
2. Blocking the N-terminus of the peptide and the lengthy linker abolish the peptide’s cell 
penetrating ability.  
3. The free compound as well as the conjugate are efflux pumps substrates and are 
rapidly expelled outside of the cell. This hypothesis could be tested by concurrent 
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application of compound and/or conjugate with efflux pump inhibitors, or by using 
bacterial mutants with attenuated efflux abilities. 
Nevertheless, the results of this study shouldn’t undermine the utility of compound-CPP 
conjugates as tools for gaining cellular penetration for drugs lacking activity in the cell as many 
examples reported the successful application of this approach (section 1.3.2).  
4.3 Peptides (RNAP) 
The third and last subchapter of this thesis handled the optimization of another class of 
molecules i.e. peptides. The first step (Alanine-scan) together with the previously published 
crystal structure, helped identify residues that are most likely solvent exposed. Thus, these 
residues are assumed to be inconsequential for binding. Next, the four identified spots were 
successfully exchanged with unnatural amino acids bearing alkyne and azide moieties. A click-
chemistry reaction was performed forming a triazole motif, achieving sidechain-to-sidechain 
macrocyclization. On the one hand, the macrocyclization did result in improved 
conformational stability and increase of α-helical content which was confirmed 
experimentally. On the other hand, in contrast to previous reports, this constrainment did not 
translate into improved biological activities. The most likely reason for such discrepancy is that 
a more conformationally flexible peptide might be required for induced-fit binding as both 
proteins undergo pronounced changes required for DNA unwinding and RNA synthesis. Due 
to the unexpected lack of in vitro activity, we couldn’t further test if the macrocyclization can 
lead to improved cellular permeability into E. coli. Future optimization by means of other 
macrocyclization motifs and lengthier linkers can produce different results. If such 
methodology still does not provide beneficial, based on the Ala-scan results exchange of 
certain residues to positively charged amino acids to convert C1 into a cell penetrating peptide 
can be attempted.  
 
The ongoing increase in drug discovery campaigns failure rates urges searching for innovative 
ideas for novel drugs in underexplored territories. Some indications have been affected by this 
innovation gap more than others e.g. anti-infectives research. One of the reasons for that was 
the increased reliance on high-throughput screening campaigns instead of rational drug 
design. These libraries lacked chemical diversity and were not honed for parameters such as 
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bacterial cell wall penetration. This thesis aimed to demonstrate the utility of rationally 
optimizing compounds from a wide drug space spectrum to address different target’s needs.  
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